Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
International Journal of Dermatology
|
May 5, 2005
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream
Carolyn M Ray, Michael Kluk, Caron M Grin, et al.
Medical Oncology (Northwood, London, England)
|
April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Bryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Case Reports in Oncology
|
May 18, 2017
Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report
Neil Oronsky, Bennett Thilagar, Carolyn M Ray, et al.
Case Reports in Oncology
|
May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome
Christina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Expert Opinion on Investigational Drugs
|
December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
Bryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
International Journal of Dermatology
|
May 5, 2005
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream
Carolyn M Ray, Michael Kluk, Caron M Grin, et al.
Medical Oncology (Northwood, London, England)
|
April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Bryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.
Case Reports in Oncology
|
May 18, 2017
Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report
Neil Oronsky, Bennett Thilagar, Carolyn M Ray, et al.
Case Reports in Oncology
|
May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome
Christina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Expert Opinion on Investigational Drugs
|
December 10, 2016
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
Bryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, et al.
Page
of 1